Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elsy Navas

Advanced Heart Failure and Transplant Cardiology Naples, FL Medical Doctor

NPI 1447493275 CMS profile 155820

399 9Th St N Ste 300, Naples, FL 34102

Open in the dashboard

General payments

$233,657

441 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,643 paid to institutions, not to them · program year 2022

Through program year 2025, Elsy Navas of Naples, FL is reported in the CMS Open Payments database as having received $233,657 across 441 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,643 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $163,839 156
2024 General $55,655 88
2023 General $4,064 52
2022 General $2,446 29
2021 General $3,379 50
2020 General $1,797 29
2019 General $2,477 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elsy Navas
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Elsy Navas were reported at $163,839. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Elsy Navas Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $2,477 $863 $224–$4,562 $163
2020 $1,797 $452 $122–$3,992 $114
2021 $3,379 $550 $159–$3,571 $132
2022 $2,446 $729 $221–$4,357 $149
2023 $4,064 $1,002 $309–$5,827 $160
2024 $55,655 $931 $273–$5,204 $164
2025 $163,839 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $68,376 51 payments
  2. Pfizer Inc. $32,722 40 payments
  3. Lexicon Pharmaceuticals, Inc. $28,103 27 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $24,201 21 payments
  5. Scpharmaceuticals Inc. $20,494 21 payments
  6. BridgeBio Pharma, Inc. $15,093 10 payments
  7. AstraZeneca Pharmaceuticals LP $12,524 17 payments
  8. Lilly USA, LLC $12,220 8 payments
  9. Abiomed $5,029 46 payments
  10. Abbott Laboratories $3,737 22 payments
  11. Other $11,158 178 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $115,284 39 payments
  2. Honoraria $43,820 13 payments
  3. Consulting Fee $31,950 9 payments
  4. Travel and Lodging $20,812 39 payments
  5. Food and Beverage $19,974 337 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,698 2 payments
  7. Education $120 2 payments
Products named General payments · program years 2019–2025
  1. AMVUTTRA $58,119 34 payments
  2. VYNDAQEL $31,077 35 payments
  3. Inpefa $28,023 22 payments
  4. JARDIANCE Diabetes $24,182 20 payments
  5. FUROSCIX $20,494 21 payments
  6. Attruby $15,093 10 payments
  7. WAINUA $12,390 12 payments
  8. JARDIANCE Diabetes $8,060 4 payments
  9. Impella $4,522 40 payments
  10. PASCAL $2,341 3 payments
  11. Other $13,746 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,257

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$15,407,100

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

57.4%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 429 $11,899,848
Amvuttra Vutrisiran Sodium Brand 14 $1,696,464
Vyndaqel Tafamidis Meglumine Brand 37 $936,281
Entresto Sacubitril/Valsartan Brand 327 $348,420
Jardiance Empagliflozin Brand 289 $332,614
Eliquis Apixaban Brand 91 $106,197
Farxiga Dapagliflozin Propanediol Brand 57 $57,652
Corlanor Ivabradine Hcl Brand 31 $16,664
Metoprolol Succinate Generic 165 $1,673
Isosorbide Dinitrate Generic 21 $1,567

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$229,944

Medicare's payments for the services billed

Medicare patients

681

Average age 80

Services billed

2,468

264 women, 417 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 73%
Arthritis 62%
Chronic kidney disease 59%
Diabetes 44%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Inpefa
  • Lexicon Pharmaceuticals, Inc. $28,001
$28,001 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $11,489
  • Lilly USA, LLC $5,460
$16,949 289 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $8,567
$8,567 — —
VYNDAQEL
  • PFIZER INC. $205
$205 37 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record